Minerva Surgical to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Minerva Surgical (Nasdaq: UTRS) announced its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Minerva Surgical (Nasdaq: UTRS) announced its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 p.m. ET. The presentation will focus on solutions for Abnormal Uterine Bleeding (AUB), highlighting the company’s commitment to developing minimally invasive options for women's uterine health.
A live audio webcast will be available through Minerva's website. The company specializes in offering alternatives to hysterectomy, emphasizing the importance of preserving the uterus while addressing AUB.
Details
News Market Reaction – UTRS
The recorded move for UTRS in the trading session of this news was -3.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA CLARA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 3:40 p.m. Eastern Time.
A live audio webcast and replay of the presentation may be accessed through the “Recent Events” section of Minerva’s website at http://ir.minervasurgical.com.
ABOUT MINERVA SURGICAL – THE UTERINE HEALTH COMPANY
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
MEDIA CONTACT
Mike Clapper
mike.clapper@minervasurgical.com
804-295-7676
INVESTOR RELATIONS CONTACT
Caroline Corner
investors@minervasurgical.com
415-202-5678
RELATED LINKS
https://www.minervasurgical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.